A Study for Reduction of Blood Lipid Peroxide, Interaction between Blood-Carotenoids and Effect on Cognitive Impairment by Ingestion of Chlorella-containing Food

A Study for Reduction of Blood Lipid Peroxide, Interaction between Blood-Carotenoids and Effect on Cognitive Impairment by Ingestion of Chlorella-containing Food - A Study for Reduction of Blood Lipid Peroxide, Interaction between Blood-Carotenoids and Effect on Cognitive Impairment by Ingestion of Chlorella-containing Food

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013754

Enrollment

Registered

2014-04-18

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of cognitive impairment

Interventions

Oral ingestion of the test product (12 months) Oral ingestion of the control product (12 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Japanese males and females aged over 60 years 2)Individuals who sign the consent document after explanation of this study 3)Individuals whose total score of Japanese version of Montreal Cognitive Assessment (MoCA-J) is under 25 points 4)Individuals whos level of plasma phosphatidylcholine hydroperoxide is relatively high value

Exclusion criteria

Exclusion criteria: 1) Individuals judged inappropriate for the study by the principal investigator 2) Individuals who routinely take proprietary drugs and health foods including beverages (chlorella foods, carotenoids and other products professing to improve lipid absorption and metabolic function) 3) Individuals who take lipid metabolism improver (e.g. ethyl icosapentate, statin, fibrate, anion exchange resin and ezetimibe) 4) Individuals who take warfarin 5) Individuals who take anti-dementia drugs, antidepressant drugs, antipsychotic drugs and anti-anxiety drugs 6) Individuals who excessively take alcohol and tobacco 7) Individuals who are sensitive to medical products and cosmetics 8) Individuals who participated in other clinical studies 9) Individuals who have anamnesis or history of present illness of head injury, cerebral stroke and epilepsia 10) Individuals who have serious hepatopathy, kidney damage and heart disease 11) Individuals whose observed data of GT is over 300mg/dL 12) Individuals whose observed data of gamma-GTP is over 2 times of upper value (male: 75 U/L, female: 45 U/L) 13) Individuals whose observed data of AST is over 2 times of upper value (male and female: 40 U/L) 14) Individuals whose observed data of ALT is over 2 times of upper value (male and female: 45 U/L) 15) Individuals whose observed data of SCR is over 2.0mg/dL

Design outcomes

Primary

Measure	Time frame
Blood lipid peroxide Cognitive impairment	—

Countries

Japan

Contacts

Public ContactTES Holdings Co., Ltd.

TES Holdings Co., Ltd. Department of Clinical Trial

info@tes-h.co.jp03-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026